Review

Surgical Extent for Oral Cancer: Emphasis on a Cut-Off Value for the Resection Margin Status: A Narrative Literature Review

Jeon Yeob Jang 1, Nayeon Choi 2 and Han-Sin Jeong 2, *

1 Department of Otolaryngology, Ajou University School of Medicine, Suwon 16499, Republic of Korea
2 Department of Otorhinolaryngology-Head and Neck Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Republic of Korea
* Correspondence: hansin.jeong@samsung.com; Tel.: +82-29-3000-8301

Simple Summary: Upfront surgical resection with safe margins is a mainstay of treatment in oral cancers. The postoperative risk stratification of the resection margin is currently determined through surgical pathology according to a cut-off width of 5 mm. However, evidence to support the validity of this cut-off point of 5 mm is not strong, and was largely obtained from retrospective clinical studies. In this review, we summarize surgical concepts for oral cancer, postoperative risk stratification based on current guidelines and propose a dynamic cut-off value for postoperative risk stratification in oral cancer.

Abstract: The optimal cut-off point of the resection margin was recently debated in oral cancer. To evaluate the current evidence of the dynamic criteria of the resection margin, a review of the available literature was performed. Studies were sourced from PubMed and EMBASE by searching for the keywords “mouth neoplasm”, “oral cancer”, “oral cavity cancer”, “oral squamous cell carcinoma”, “tongue cancer”, “margins of excision”, “surgical margin” and “resection margin”. We found approximately 998 articles on PubMed and 2227 articles on EMBASE. A total of 3225 articles was identified, and 2763 of those were left after removing the duplicates. By applying advanced filters about the relevance of the subjects, these were narrowed down to 111 articles. After the final exclusion, 42 full-text articles were reviewed. The universal cut-off criteria of 5 mm used for determining the resection margin status has been debated due to recent studies evaluating the impact of different margin criteria on patient prognosis. Of note, the degree of the microscopic extension from the gross tumor border correlates with tumor dimensions. Therefore, a relatively narrow safety margin can be justified in early-stage oral cancer without the additional risk of recurrence, while a wide safety margin might be required for advanced-stage oral cancer. This review suggests a surgical strategy to adjust the criteria for risk grouping and adjuvant treatments, according to individual tumor dimensions or characteristics. In the future, it might be possible to establish individual tumor-specific surgical margins and risk stratification during or after surgery. However, the results should be interpreted with caution because there is no strong evidence (e.g., prospective randomized controlled studies) yet to support the conclusions. Our study is meaningful in suggesting future research directions and discussions.

Keywords: mouth neoplasm; surgery; margins of excision; treatment outcomes

1. Introduction

Oral cancer leads to major morbidity and mortality rates among head and neck cancers, and accounts for over 370,000 new cases and 170,000 deaths per year worldwide [1]. The five-year survival rate of oral cancer patients remains limited (50–65%) [2]. An improved understanding of the tumor biology and clinical features has led to recent changes in the American Joint Committee on Cancer (AJCC) tumor–node–metastasis (TNM) classification,
to incorporate the depth of invasion (DOI) and the extranodal extension of lymph node metastasis as major determinants of the staging system [3].

Upfront surgery, including wide excision with adequate margins in all three dimensions, is a mainstay of treatment, and should be offered as the initial treatment when tumors are operable [4,5]. Surgery includes the neck lymphatic basins even in clinically node-negative patients, and it was proven in recent randomized controlled trials to impart the survival benefit of prophylactic neck dissection in early-stage oral cancer (T1-2N0) [6,7]. Sentinel lymph node biopsy has been reported to accurately predict the presence of pathological lymph node metastasis in early-stage oral cancer, and it is considered an alternative to elective neck dissection where expertise for this procedure is available [8–12].

According to the current treatment guidelines of the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN guidelines) [4], the criteria of clear resection margin is considered to be 5 mm, regardless of the primary tumor’s size or characteristics. However, the supporting evidence for a cut-off point of 5 mm is not strong and has recently been debated, especially in early-stage oral cancer. In addition, several researchers have suggested a differential clinical significance to mucosal versus deep margins. Thus, the criteria of clear resection margin have been challenged based on the individual tumor characteristics, while the universal cut-off criterion of 5 mm is still adopted in the current treatment guidelines.

In this review, we summarized surgical concepts for oral cancer, postoperative risk stratification and current guidelines with a particular focus on the cut-off point for the resection margin from the relevant literature. In addition, we proposed a so-called dynamic cut-off value (rather than a fixed one) for postoperative risk stratification in oral cancer management based on recent research.

2. Method

A database search using the online databases PubMed (https://pubmed.ncbi.nlm.nih.gov/) and EMBASE (https://www.embase.com/) was conducted on 30 August 2022 (Figure 1). The following keywords were used in the search: “mouth neoplasm”, “oral cancer”, “oral cavity cancer”, “oral squamous cell carcinoma”, “tongue cancer”, “margins of excision”, “surgical margin”, “resection margin”. The inclusion criteria were articles regarding the impact of surgical margin on survival. Exclusion criteria were studies not related, nonrelevant articles, unavailable full-text articles and articles with insufficient data.
3. Results

We found approximately 998 articles on PubMed and 2227 articles on EMBASE. A total of 3225 articles was identified, and 2763 of those were left after the removal of the duplicates. After applying advanced filters through an abstract review, 2632 nonrelevant articles were excluded. The remaining 111 full-text articles were assessed for eligibility. After the final exclusion (studies not related, nonrelevant articles, unavailable full-text articles and those with insufficient data), the resulting 42 full-text articles were reviewed. Among them, regarding the subject of the prognostic significance according to the cut-off points of resection margin length, 12 studies were selected for the final analysis (Table 1). Regarding the subject of the dynamic cut-off points, four articles were selected for the final analysis (Table 2).

4. Discussion

4.1. Surgical Concept for Oral Cancer

The primary aim of curative surgery for oral cancer is the complete removal of local or locoregional disease to achieve a long-term disease-free status. Along with this fundamental basis of surgical resection, the functional preservation of normal tissues around tumors is essential to maintain patient quality of life within oncological safety [13].

In addition to the complete removal of clinically overt lesions, the identification and removal of potentially malignant (premalignant) lesions or clinically undetectable (microscopic) diseases are important factors for disease control. For example, high-grade dysplasia around cancerous lesions is a common target for resection, although the extent of high-grade dysplasia is not a criterion for the current tumor (T) classification in oral cancer [14]. Similarly, the primary surgery includes the surgical removal of occult lymph node metastasis, even in patients without a clinically detectable lesion (elective lymph node dissection or sentinel lymph node biopsy) [6].

This surgical principle is valid for the resection of the primary site of oral cancer, which includes normal or normal-appearing surrounding tissues at a certain margin (length or width) from clinical (gross) cancer lesions (Figure 2). This is the so-called surgical safety margin. While there is no high-level evidence for a specific cut-off value of the surgical safety margin [15], its clinical importance and indispensability have been accepted by most surgeons to accomplish the surgical aim safely.

![Figure 2. Resection of oral cancer with irregular three-dimensional growth. (a) Setting of appropriate safety margin in oral cancer surgery. Dotted line indicates mucosal safety margin; (b) surgical specimen that includes primary tumor and normal surrounding tissues. The resection margin includes mucosal and deep margins.](image-url)
More practically, a surgical safety margin in oral cancer surgery is necessary due to the following reasons:

4.1.1. Irregular Three-Dimensional Growth of Primary Tumors

The current surgical approach to primary tumors largely depends on a visual inspection, palpation and preoperative imaging, all of which estimate the tumor to be a three-dimensional ellipsoid sphere. However, pathological evaluations of surgical specimens frequently reveal irregular three-dimensional growth patterns of primary tumors, such as a “finger-like” pushing pattern, satellite tumor nodules located away from the main tumor and tumor budding in oral cancers [16]. There is a clear limitation in precisely delineating the three-dimensional growth of tumors and irregular local extension in either surface or depth [17]. Therefore, surgery includes normal surrounding tissues at a certain margin from the gross tumor, so that the tumors can be removed completely with surgery, even in cases with an irregular local tumor infiltration.

4.1.2. Difficulty in the Delineation of Normal to Tumor Margin during Surgery

The greatest weakness of the current surgery is its inability to clearly identify tumor boundaries on the mucosal surface or in deep tissues during surgery. It is often not possible to reflect accurately the boundaries of pathological tumors with the naked eye or even using magnified views with a microscope or endoscope. The limitations of deep resection frequently result in a suboptimal margin status. Some researchers have attempted real-time imaging, such as ultrasonography during surgery [18,19] or in vivo imaging [20–23]; however, a common and broad application of real-time imaging to a practice requires further development and clinical research. In short, a surgical strategy for complete tumor removal can be accomplished under the current surgical approach only with a tumor resection that includes safety margins from the boundaries of presumed gross tumors.

4.1.3. Removal of Potential (Future) Malignant Sources

Even though all gross or microscopic tumor cells are removed during surgery (no actual tumor cells remain at the tumor resection margin), it is necessary to remove the adjacent tissue that has the potential to recur for long-term tumor control of the disease. These lesions include normal-looking tissues with premalignant characteristics and molecular alterations [24]. Even when the boundary of the tumor can be identified accurately and pathologically, it is safer to remove a certain amount of the surrounding normal-looking tissue at the boundary of the tumor to prevent future cancer recurrence.

4.2. Resection Margin Status and Risk Stratification

According to the current treatment guidelines (NCCN guidelines) [4], the resection margin status is divided into three categories. These categories are the criteria to predict the risk of tumor recurrence and to determine the best adjuvant treatment.

(1) Clear margin: defined as the distance from the invasive tumor front of 5 mm or more from the resected margin on final histopathology;
(2) Close margin: defined as the distance from the invasive tumor front to the resected margin less than 5 mm on final histopathology;
(3) Positive margin: defined as carcinoma in situ or invasive carcinoma at the margin of resection.

However, the supporting evidence for a cut-off point of 5 mm for the resection margin status is not strong, and was mostly obtained from retrospective clinical studies or surgeons’ experiences [15]. Moreover, the current cut-off point (5 mm) applies to all tumor stages (T1–4), regardless of individual tumor characteristics. According to the current treatment guidelines [4], the representative adverse features after surgery are positive resection margins and the extranodal extension of lymph node metastasis. In addition, pT3–4, N2–3, perineural invasion and lymphovascular invasion are risk factors for disease recurrence.
Intriguingly, a close surgical margin is included in the postoperative adverse features in the latest version of the NCCN guidelines [4].

To achieve 5 mm postoperative pathological margins, the surgical method generally requires a safety margin of approximately 10–15 mm. The distance (10–15 mm) of this on-site surgical margin is based on both the tumor characteristics of irregular growth and expected postresection tissue shrinkage (30–70%) [25,26].

4.3. Criteria for a Close Resection Margin and Its Clinical Significance

Many clinical studies have investigated the optimal resection margin or margin length (width) in oral cancer surgery [14,25–41]. A recent meta-analysis of the resection margin size in oral squamous cell carcinoma (SCC) suggested that a 5 mm pathologic margin is the minimum acceptable value [42]. However, the five studies included in the meta-analysis had heterogeneities in their definitions of a close/positive resection margin and the status of adjuvant therapy.

The unanimous conclusions across studies are that the risk of local recurrence increases in cases with a positive surgical margin and is reduced with negative (clear) surgical margins after oral cancer surgery [14,24,31,33,40,41,43]. However, the impact of close surgical margins on local recurrences is still under debate (Table 1) [14,27,33,40,41,43–47]. It has been argued that the cut-off point of close margins could be 1 mm [44], 1.6 mm (in oral and oropharyngeal cancer) [35], 2 mm (in buccal mucosa cancer) [30], 3 mm [27], 5 mm [42] or 7 mm [40]. Particularly in early-stage oral cancer, the best margin size is more controversial. A previous study of 295 patients with pT1/T2 oral cancer reported that the size of the resection margin did not influence the local control rate [48]. Another study analyzed 382 patients with cT1/T2 oral cancer and found no significant increase in the local recurrence rate with a close resection margin, compared with a clear resection margin [49].

In addition, many researchers have imposed differential clinical significance to mucosal versus deep margins. Involved and close resection margins were more common in deep margins than in mucosal margins [50]. For example, 37.8% of oral cancer patients had a deep resection margin of less than 5 mm after en bloc resection, while 24.4% had a close mucosal resection margin [35]. Notably, a study of 187 patients with oral SCC reported that the local recurrence rate (64.0%) of a close (<4 mm) deep resection margin was higher than the 45.2% recurrence rate of the close mucosal resection margin [51]. Thus, the close deep resection margins occur more frequently and elicit a detrimental impact on prognosis compared with close mucosal resection margins, suggesting the requirement for the cautious consideration of the tumor-specific deep resection margin.

4.4. Dynamic Cut-Off Values for Postoperative Risk Stratification

With advances in our understanding of tumor biology, several interesting results have been published regarding different criteria of close surgical margins.

In human papilloma virus (HPV)-positive oropharyngeal cancer, the cut-off point for the resection margin for risk stratification decreased to 1–2 mm (when compared with the traditional margin criteria of 5 mm), based on the different (favorable) behaviors of HPV-related cancers [52,53]. This finding suggests that the criteria of risk grouping and adjuvant treatments can be adjusted based on individual tumor biology, even in oral cancers.

Currently, there are several supporting pieces of evidence suggesting the need for a dynamic margin cut-off system in oral cancer (Table 2). First, the surgical safety margin highly depends on the microscopic extension from the gross tumor border. In microscopically infiltrative cancers, a large amount of surrounding tissue must be included to avoid residual cancer cells. An interesting finding was that the degree of microscopic extension from the gross tumor border was found to correlate with tumor dimensions in oropharyngeal, oral and hypopharyngeal cancers [54–56]. That is, when the tumor is small or in the early growth stage, the degree of local invasion around the tumor is small; when the tumor is large, it increases (Figure 3). Therefore, a relatively narrow safety margin (or resection
Cancers 2022, 14, 5702

margin) can be applied in early-stage oral cancer, while a wide safety margin would likely be required in advanced-stage oral cancer.

Table 1. Prognostic significance and local recurrence rate according to the cut-off points of resection margin length in surgically treated oral squamous cell carcinomas.

| Published Article First Author | Publication Year | Study Design and Number of Patients | Cut-Off Points of the Resection Margin | Local Recurrence Rate | Disease-Free Survival | Overall Survival (5Y) |
|-------------------------------|-----------------|-------------------------------------|----------------------------------------|-----------------------|-----------------------|----------------------|
| Loree [41]                   | 1990            | Retrospective single center (N = 398) | <5 mm                                  | 52.0%                 | 60.9%                 |
| Sutton [33]                   | 2003            | Retrospective single center (N = 200) | Involved                               | 33%                   | 36.0%                 | 60.0%                |
| Weijers [34]                  | 2004            | Retrospective single center (N = 68) | ≤5 mm                                  | 6.7%                  | 7.9%                  |                      |
| Garzino-Demo [37]            | 2006            | Retrospective single center (N = 245) | <5 mm                                  | 48.0%                 |                      | 65.0%                |
| Binahmed [43]                 | 2007            | Retrospective single center (N = 425) | Involved                               | 38.7%                 | 58.3%                 | 68.4%                |
| Liao [40]                     | 2008            | Retrospective single center (N = 827) | 3–11 mm in 1 mm intervals              | On multivariate analysis, resection margin ≤ 7 mm was significantly associated with decreased local disease control |
| Nason [27]                   | 2009            | Retrospective single center (N = 277) | Involved                               | 48.3%                 | 48.5%                 | 62.6%                |
| Kurita [14]                   | 2010            | Retrospective single center (N = 148) | 1 mm                                   | 33.3%                 |                      | 70.5%                |
| Tasche [44]                   | 2017            | Retrospective single center (N = 432) | Involved                               | 44.0%                 | 28.0%                 |                      |
| Singh [45]                    | 2020            | Retrospective single center (N = 451) | ≤2 mm                                  | 88.9%                 |                      |                      |
| Jain [46]                     | 2020            | Retrospective single center (N = 612) | Involved                               | 57.7%                 |                      |                      |
| Lin [47]                      | 2021 Taiwan Cancer Registry (N = 15,654) |                      | Involved                               | 46.7%                 |                      |                      |
Table 2. Supporting evidence for the dynamic criteria of cut-off margin lengths according to tumor dimension in oral cancer.

| Tumor Variables (Reference No.) | Number of Patients | Findings                  | p-Value | p-Value |
|---------------------------------|--------------------|---------------------------|---------|---------|
| Tumor status [55]               |                    |                           |         |         |
| T1-2                            | 90                 | Microscopic infiltration  |         |         |
|                                 |                    | 0.96 ± 0.54 mm            | <0.001  |         |
|                                 |                    | 1.76 ± 1.20 mm            |         |         |
| Depth of invasion [57]          | 100                | PNI                       |         |         |
| <4 mm                           | 2%                 |                           |         |         |
| ≥4 mm                           | 38%                | <0.01                     | 28%     | 0.02    |
| MTR in deep resection [58]      | 501                | Two-year locoregional     |         |         |
| control rate                    |                    |                           |         |         |
| >0.3                            | 94%                |                           |         |         |
| ≤0.3                            | 87%                |                           |         |         |
| Log MTR [59]                    | 302                | Five-year disease-specific survival |         |         |
| >33%                            | HR 1               |                           | <0.001  |         |
| ≤33%                            | HR 2.48            |                           |         |         |

HR: hazard ratio; LVI: lymphovascular invasion; MTR: margin to thickness ratio; PNI: perineural invasion.

Figure 3. Microscopic infiltration depending on the gross tumor dimension. (a) A limited microscopic infiltration in a small-sized primary tumor; (b) an increased degree of microscopic infiltration in a large primary tumor.

Besides a tumor’s dimensions, the depth of invasion is also known to be associated with adverse tumor characteristics. Larson et al. [57] recently reviewed one hundred pathologic specimens of oral cancers and found that the depth of invasion of more than 4 mm showed significantly increased rates of adverse features, including perineural invasion and lymphovascular invasion (Table 2).

There is other supporting evidence that has attempted to address the question of whether small oral cancers require the same margin clearance as large tumors [58]. The authors evaluated the association between the ratio of the closest margin to tumor thickness with local control and survival in oral cancers [58]. In this study, a margin-to-tumor thickness ratio (MTR) of 0.3 was set as a cut-off point, and an MTR of ≤0.3 was a predictor of local failure and disease-specific death (Table 2). These results suggest that a wider deep resection margin is required as tumor thickness increases. Another study further evaluated the value of this dynamic margin criteria and found that a log MTR of <33% was a predictor of less favorable outcome in the disease-specific survival of oral cancer [59]. Taken together, recent evidence suggests the need for dynamic resection margin criteria according to a tumor’s dimensions or the depth of invasion in oral cancer.

However, the level of evidence to support our conclusion is low. There is still no standard tool for applying individual tumor characterization to surgery (especially the
surgical margin of the primary tumor). Therefore, additional clinical and basic studies are needed in the future.

5. Conclusions

In summary, the current treatment guidelines adopt a cut-off point of 5 mm as a single reference value for postoperative risk stratification, without considering tumor characteristics, dimensions or clinical tumor stage. However, as our understanding of tumor biology increases, it could be possible to establish tumor-specific surgical margins (risk stratification) either during or after surgery.

Author Contributions: Conceptualization, J.Y.J. and H.-S.J.; Data curation, J.Y.J. and N.C.; Formal analysis, J.Y.J. and H.-S.J.; Funding acquisition, J.Y.J. and H.-S.J.; Investigation, J.Y.J. and H.-S.J.; Methodology, J.Y.J. and N.C.; Supervision, H.-S.J.; Validation, J.Y.J. and H.-S.J.; Writing—original draft, J.Y.J. and N.C.; Writing—review and editing, H.-S.J. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by grants from the Samsung Medical Center (grant numbers: OTX0001031 and PHX0201451) and was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health and Welfare, Republic of Korea (grant number: HR21C1003). The above funders had no role in the study design, data collection, data analysis and interpretation, writing of the manuscript or the decision to submit this manuscript for publication.

Acknowledgments: The authors appreciate Woohyun Cho (Ajou University School of Medicine, Medical Information and Media Center) for the medical illustration of Figures 2 and 3.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021, 71, 209–249. [CrossRef] [PubMed]

2. Zanoni, D.K.; Montero, P.H.; Migliacci, J.C.; Shah, J.P.; Wong, R.J.; Ganly, I.; Patel, S.G. Survival outcomes after treatment of cancer of the oral cavity (1985–2015). Oral Oncol. 2019, 90, 115–121. [CrossRef] [PubMed]

3. Lydiatt, W.M.; Patel, S.G.; O’Sullivan, B.; Brandwein, M.S.; Ridge, J.A.; Migliacci, J.C.; Loomis, A.M.; Shah, J.P. Head and Neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual. CA Cancer J. Clin. 2017, 67, 122–137. [CrossRef] [PubMed]

4. National Comprehensive Cancer Network. Head and Neck Cancers. Version 3. 2021. Available online: https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf (accessed on 27 July 2021).

5. Patel, V.; Galloway, T.J.; Liu, J.C. The impact of positive margin on survival in oral cavity squamous cell carcinoma. Oral Oncol. 2021, 122, 105499. [CrossRef]

6. D'Cruz, A.K.; Vaish, R.; Kapre, N.; Dandekar, M.; Gupta, S.; Hawaldar, R.; Agarwal, J.P.; Pantvaidya, G.; Chaukar, D.; Deshmukh, A.; et al. Elective versus therapeutic neck dissection in node-negative oral cancer. N. Engl. J. Med. 2015, 373, 521–529. [CrossRef] [PubMed]

7. Pantvaidya, G.; Rao, K.; D'Cruz, A. Management of the neck in oral cancers. Oral Oncol. 2020, 100, 104476. [CrossRef]

8. Civantos, F.J.; Zitsch, R.P.; Schuller, D.E.; Agrawal, A.; Smith, R.B.; Nason, R.; Petruzelli, G.; Gourin, C.G.; Wong, R.J.; Ferris, R.L.; et al. Sentinel lymph node biopsy accurately stages the regional lymph nodes for T1-T2 oral squamous cell carcinomas: Results of a prospective multi-institutional trial. J. Clin. Oncol. 2010, 28, 1395–1400. [CrossRef]

9. Garrel, R.; Poissonnet, G.; Moya Planas, A.; Fakhry, N.; Dolivet, G.; Lallemand, B.; Sarini, J.; Vergez, S.; Guelfucci, B.; Choussy, O.; et al. Equivalence randomized trial to compare treatment on the basis of sentinel node biopsy versus neck node dissection in operable T1-T2N0 oral and oropharyngeal cancer. J. Clin. Oncol. 2020, 38, 4010–4018. [CrossRef]

10. Hasegawa, Y.; Tsukahara, K.; Yoshimoto, S.; Miura, K.; Yokoyama, J.; Hirano, S.; Uemura, H.; Sugawara, M.; Yoshizaki, T.; Homma, A.; et al. Neck dissections based on sentinel lymph node navigation versus elective neck dissections in early oral cancers: A randomized, multicenter, and noninferiority trial. J. Clin. Oncol. 2021, 39, 2025–2036. [CrossRef]

11. Cramer, J.D.; Sridharan, S.; Ferris, R.L.; Duvvuri, U.; Samant, S. Sentinel lymph node biopsy versus elective neck dissection for stage I to II oral cavity cancer. Laryngoscope 2019, 129, 162–169. [CrossRef]

12. Bowe, C.M.; Shastri, M.; Gulati, A.; Norris, P.; Corrigan, A.; Barrett, A.W.; Bisase, B. Challenges and outcomes in establishing a sentinel lymph node biopsy service for oral squamous cell carcinoma in a regional district specialist hospital. Br. J. Oral Maxillofac. Surg. 2021, 59, 217–221. [CrossRef] [PubMed]
13. Meier, J.D.; Oliver, D.A.; Varvarigos, M.A. Surgical margin determination in head and neck oncology: Current clinical practice. The results of an International American Head and Neck Society Member Survey. *Head Neck* **2005**, 27, 952–958. [CrossRef] [PubMed]

14. Kurita, H.; Nakamichi, Y.; Nishizawa, R.; Xiao, T.; Kamata, T.; Koike, T.; Kobayashi, H. Impact of different surgical margin conditions on local recurrence of oral squamous cell carcinoma. *Oral Oncol.* **2010**, 46, 814–817. [CrossRef]

15. Bulbul, M.G.; Zenga, J.; Tarabichi, O.; Parikh, A.S.; Sethi, R.K.; Robbins, K.T.; Puram, S.V.; Varvarigos, M.A. Margin practices in oral cavity cancer resections: Survey of American head and neck society members. *Laryngoscope* **2021**, 131, 782–787. [CrossRef] [PubMed]

16. Xu, B.; Salama, A.M.; Valero, C.; Yuan, A.; Khimraj, A.; Saliba, M.; Zanoni, D.K.; Ganly, I.; Patel, S.G.; Katabi, N.; et al. The prognostic role of histologic grade, worst pattern of invasion, and tumor budding in early oral tongue squamous cell carcinoma: A comparative study. *Virchows Arch.* **2021**, 479, 597–606. [CrossRef] [PubMed]

17. Kain, J.J.; Birkeland, A.C.; Udayakumar, N.; Morlandt, A.B.; Stevens, T.M.; Carroll, W.R.; Rosenthal, E.L.; Warram, J.M. Surgical margins in oral cavity squamous cell carcinoma: Current practices and future directions. *Laryngoscope* **2020**, 130, 128–138. [CrossRef] [PubMed]

18. Tarabichi, O.; Bulbul, M.G.; Kanumuri, V.V.; Faquin, W.C.; Juliano, A.F.; Cunnane, M.E.; Varvares, M.A. Utility of intraoral ultrasound in managing oral tongue squamous cell carcinoma: Systematic review. *Laryngoscope* **2019**, 129, 662–670. [CrossRef]

19. de Koning, K.J.; Koppes, S.A.; de Bree, R.; Dankbaar, J.W.; Willems, S.M.; van Es, R.J.J.; Noorlag, R. Feasibility study of ultrasound-guided resection of tongue cancer with immediate specimen examination to improve margin control–comparison with conventional treatment. *Oral Oncol.* **2021**, 116, 105249. [CrossRef]

20. Fatakdawala, H.; Poti, S.; Zhou, F.; Sun, Y.; Bec, J.; Liu, J.; Yankelevich, S.; Gondour-Edwards, R.F.; Farwell, D.G.; et al. Multimodal in vivo imaging of oral cancer using fluorescence lifetime, photoacoustic and ultrasound techniques. *Biomed. Opt. Express* **2013**, 4, 1724–1741. [CrossRef]

21. Noorlag, R.; de Bree, R.; Witjes, M.J.H. Image-guided surgery in oral cancer: Toward improved margin control. *Curr. Opin. Oncol.* **2022**, 34, 170–176. [CrossRef]

22. Wu, C.; Gleystee, J.; Teraphongphom, N.T.; Li, Y.; Rosenthal, E. In-vivo optical imaging in head and neck oncology: Basic principles, clinical applications and future directions. *Int. J. Oral Sci.* **2018**, 10, 10. [CrossRef] [PubMed]

23. Young, K.; Ma, E.; Kejriwal, S.; Nielsen, T.; Aulakh, S.S.; Birkeland, A.C. Intraoperative in vivo imaging modalities in head and neck cancer surgical margin delineation: A systematic review. *Cancers* **2022**, 14, 3416. [CrossRef]

24. Brennan, J.A.; Mao, L.; Hruban, R.H.; Boyle, J.O.; Eby, Y.J.; Koch, W.M.; Goodman, S.N.; Sidransky, D. Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. *N. Engl. J. Med.* **1995**, 332, 429–435. [CrossRef] [PubMed]

25. Mistry, R.C.; Qureshi, S.S.; Kumar, C. Post-resection mucosal margin shrinkage in oral cancer: Quantification and significance. *J. Surg. Oncol.* **2005**, 91, 131–133. [CrossRef] [PubMed]

26. Johnson, R.E.; Sigman, J.D.; Funk, G.F.; Robinson, R.A.; Hoffman, H.T. Quantification of surgical margin shrinkage in the oral cavity. *Head Neck* **1997**, 19, 281–286. [CrossRef]

27. Nason, R.W.; Binahmed, A.; Pahlak, K.A.; Abdoh, A.A.; Sándor, G.K. What is the adequate margin of surgical resection in oral cancer? *Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod.* **2009**, 107, 625–629. [CrossRef]

28. Cheng, A.; Cox, D.; Schmidt, B.L. Oral squamous cell carcinoma margin discrepancy after resection and pathologic processing. *J. Oral Maxillofac. Surg.* **2008**, 66, 523–529. [CrossRef]

29. Alicandri-Ciufelli, M.; Bonali, M.; Piccinni, A.; Marra, L.; Ghidini, A.; Cusolo, E.M.; Maiorana, A.; Presutti, L.; Conte, P.F. Surgical margins in head and neck squamous cell carcinoma: What is ‘close’? *Eur. Arch. Otorhinolaryngol.* **2013**, 270, 2603–2609. [CrossRef]

30. Dixit, S.; Vyas, R.K.; Toparani, R.B.; Baboo, H.A.; Patel, D.D. Surgery versus surgery and postoperative radiotherapy in squamous cell carcinoma of the buccal mucosa: A comparative study. *Ann. Surg. Oncol.* **1998**, 5, 502–510. [CrossRef]

31. Hinmi, M.L.; Ferlito, A.; Brandwein-Gensler, M.S.; Takes, R.P.; Silver, C.E.; Westra, W.H.; Seethala, R.R.; Rodrigo, J.P.; Corry, J.; Bradford, C.R.; et al. Surgical margins in head and neck cancer surgery: A contemporary review. *Head Neck* **2013**, 35, 1362–1370. [CrossRef]

32. Oliver, R.J.; Clarkson, J.E.; Conway, D.I.; Glenny, A.; Macluskey, M.; Pavitt, S.; Sloan, P.; Panel, C.E.; Worthington, H.V. Interventions for the treatment of oral and oropharyngeal cancers: Surgical treatment. *Cochrane Database Syst. Rev.* **2007**, 17, CD006205. [CrossRef]

33. Sutton, D.N.; Brown, J.S.; Rogers, S.N.; Vaughan, E.D.; Woolgar, J.A. The prognostic implications of the surgical margin in oral squamous cell carcinoma. *Int. J. Oral Maxillofac. Surg.* **2003**, 32, 30–34. [CrossRef] [PubMed]

34. Weijers, M.; Snow, G.B.; Bezemer, D.P.; van der Wal, J.E.; van der Waal, I. The status of the deep surgical margins in tongue and floor of mouth squamous cell carcinoma and risk of local recurrence; an analysis of 68 patients. *Int. J. Oral Maxillofac. Surg.* **2004**, 33, 146–149. [CrossRef]

35. Wong, L.S.; McMahon, J.; Devine, J.; McLellan, D.; Thompson, E.; Farrow, A.; Moos, K.; Ayoub, A. Influence of close resection margins on local recurrence and disease-specific survival in oral and oropharyngeal carcinoma. *Br. J. Oral Maxillofac. Surg.* **2012**, 50, 102–108. [CrossRef] [PubMed]
36. El-Husseiny, G.; Kandil, A.; Jamshed, A.; Khafaga, Y.; Saleem, M.; Allam, A.; Al-Raihi, N.; Al-Amro, A.; Rostom, A.Y.; Abuzeid, M.; et al. Squamous cell carcinoma of the oral tongue: An analysis of prognostic factors. *Br. J. Oral Maxillofac. Surg.* 2000, 38, 193–199. [CrossRef]

37. Garzino-Demo, P.; Dell’Acqua, A.; Dalmaso, P.; Fasolis, M.; La Terra Maggiore, G.M.; Ramieri, G.; Berrone, S.; Rampino, M.; Schena, M. Clinicopathological parameters and outcome of 245 patients operated for oral squamous cell carcinoma. *J. Craniofacial Surg.* 2006, 17, 344–350. [CrossRef]

38. Hicks, W.L., Jr; North, J.H., Jr; Loree, T.R.; Maamoun, S.; Mullins, A.; Orner, J.B.; Bakamjian, V.Y.; Shedd, D.P. Surgery as a single modality therapy for squamous cell carcinoma of the oral tongue. *Ann. J. Otolaryngol.* 1998, 19, 24–28. [CrossRef]

39. Kademeni, D.; Bell, R.B.; Bagheri, S.; Holmgren, E.; Dierks, E.; Potter, B.; Homer, L. Prognostic factors in intraoral squamous cell carcinoma: The influence of histologic grade. *J. Oral Maxillofac. Surg.* 2005, 63, 1599–1605. [CrossRef]

40. Liao, C.T.; Chang, J.T.; Wang, H.M.; Ng, S.H.; Hsieh, C.; Lee, L.Y.; Lin, C.H.; Chen, I.H.; Huang, S.F.; Cheng, A.J.; et al. Analysis of risk factors of predictive local tumor control in oral cavity cancer. *Ann. Surg. Oncol.* 2008, 15, 915–922. [CrossRef]

41. Anderson, C.R.; Sisson, K.; Moncrieff, M. A meta-analysis of margin size and local recurrence in oral squamous cell carcinoma. *Oral Oncol.* 2015, 51, 464–469. [CrossRef]

42. Binahmed, A.; Nason, R.W.; Abdoh, A.A. The clinical significance of the positive surgical margin in oral cancer. *Oral Oncol.* 2007, 43, 780–784. [CrossRef]

43. Tasche, K.K.; Buchakjian, M.R.; Pagedar, N.A.; Sperry, S.M. Definition of “close margin” in oral cancer surgery and association of margin distance with local recurrence rate. *JAMA Otolaryngol. Head Neck Surg.* 2017, 143, 1166–1172. [CrossRef] [PubMed]

44. Singh, A.; Mishra, A.; Singhvi, H.; Sharin, F.; Bal, M.; Laskar, S.G.; Prabhash, K.; Chaturvedi, P. Optimum surgical margins in squamous cell carcinoma of the oral tongue: Is the current definition adequate? *Oral Oncol.* 2020, 111, 104938. [CrossRef] [PubMed]

45. Jain, P.V.; Sharan, R.; Manikanth, K.; Clark, G.M.; Chatterjee, S.; Mallick, I.; Roy, P.; Arun, P. Redefining adequate margins in oral squamous cell carcinoma: Outcomes from close and positive margins. *Eur. Arch. Otorhinolaryngol.* 2020, 277, 1155–1165. [CrossRef] [PubMed]

46. Lin, M.C.; Lee, Y.S.; Chiang, C.J.; Ko, J.Y.; Wang, C.P.; Yang, T.L.; Chen, T.C.; Chen, C.N.; Chen, H.L.; Liao, C.T.; et al. Adequate surgical margins for oral cancer: A Taiwan cancer registry national database analysis. *Oral Oncol.* 2021, 119, 105358. [CrossRef]

47. Barry, C.P.; Ahmed, F.; Rogers, S.N.; Lowe, D.; Bekiroglu, F.; Brown, J.S.; Shaw, R.J. Influence of surgical margins on local recurrence in T1/T2 oral squamous cell carcinoma. *Head Neck* 2015, 37, 1176–1180. [CrossRef]

48. Barry, C.P.; Katre, C.; Papa, E.; Brown, J.S.; Shaw, R.J.; Bekiroglu, F.; Lowe, D.; Rogers, S.N. De-escalation of surgery for early oral cancer—is it oncologically safe? *Br. J. Oral Maxillofac. Surg.* 2013, 51, 30–36. [CrossRef]

49. Chen, T.C.; Wang, C.P.; Ko, J.Y.; Yang, T.L.; Lou, P.J. The impact of pathologic close margin on the survival of patients with early stage oral squamous cell carcinoma. *Oral Oncol.* 2012, 48, 623–628. [CrossRef]

50. Yanamato, S.; Yamada, S.; Takahashi, H.; Yoshitomi, I.; Kawasaki, G.; Ikeda, H.; Minamizato, T.; Shiraishi, T.; Fujita, S.; Ikeda, T.; et al. Clinicopathological risk factors for local recurrence in oral squamous cell carcinoma. *Int. J. Oral Maxillofac. Surg.* 2012, 41, 1195–1200. [CrossRef]

51. Nichols, A.C.; Theurer, J.; Prisman, E.; Read, N.; Berthelet, E.; Tran, E.; Fung, K.; de Almeida, J.R.; Bayley, A.; Goldstein, D.P.; et al. Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): An open-label, phase 2, randomised trial. *Lancet Oncol.* 2019, 20, 1349–1359. [CrossRef]

52. Farris, R.L.; Flmand, Y.; Weinstein, G.S.; Li, S.L.; Quon, H.; Mehra, R.; Garcia, J.J.; Chung, C.H.; Gillison, M.L.; Duvvuri, U.; et al. Transoral robotic surgical resection followed by randomization to low- or standard-dose IMRT in resectable p16+ locally advanced oropharynx cancer: A trial of the ECOG-ACRIN Cancer Research Group (E3311). *J. Clin. Oncol.* 2020, 38, 6500. [CrossRef]

53. Shin, J.; Lee, J.; Hwang, N.; Choi, S.Y.; Park, W.; Choi, N.; Son, Y.I.; Cho, J.; Jeong, H.S. Tumor dimension-dependent microscopic extensions of hypopharyngeal cancer: Therapeutic implications for larynx-preserving hypopharyngectomy. *J. Surg. Oncol.* 2021, 123, 872–880. [CrossRef] [PubMed]

54. Jang, J.Y.; Choi, N.; Ko, Y.H.; Chung, M.K.; Son, Y.I.; Baek, C.H.; Baek, K.H.; Jeong, H.S. Differential impact of close surgical margin on local recurrence according to primary tumor size in oral squamous cell carcinoma. *Ann. Surg. Oncol.* 2017, 24, 1698–1706. [CrossRef] [PubMed]

55. Lee, J.; Yoon, N.; Choi, S.Y.; Moon, J.H.; Chung, M.K.; Son, Y.I.; Ko, Y.H.; Jeong, H.S.; Baek, C.H. Extent of local invasion and safe resection in cT1-2 tonsil cancer. *J. Surg. Oncol.* 2013, 107, 469–473. [CrossRef] [PubMed]

56. Larson, A.R.; Kemmer, J.; Fommeister, E.; El-Sayed, I.; Ha, P.; George, J.; Ryan, W.; Chan, E.; Heaton, C. Beyond depth of invasion: Adverse pathologic tumor features in early oral tongue squamous cell carcinoma. *Laryngoscope* 2020, 130, 1715–1720. [CrossRef] [PubMed]

57. Heiduschka, G.; Virk, S.A.; Palme, C.E.; Ch’ng, S.; Elliot, M.; Gupta, R.; Clark, J. Margin to tumor thickness ratio—A predictor of local recurrence and survival in oral squamous cell carcinoma. *Oral Oncol.* 2016, 55, 49–54. [CrossRef] [PubMed]

58. Huang, C.Y.; Lin, Y.S.; Kang, B.H.; Chang, K.P.; Chi, C.C.; Lin, M.Y.; Su, H.H.; Chang, T.S.; Lee, H.P.; Lee, C.C. Log margin-to-thickness ratio improves disease-specific survival prediction in oral cancer: A single cancer centre database. *Clin. Otolaryngol.* 2019, 44, 63–69. [CrossRef]